We conducted a prospective randomized trial to compare the clinical impact of conventional risk factor modification to that associated with the addition of coronary artery calcium (CAC) scanning.
hypothesis that performing CAC scanning of asymptomatic volunteers would lead to a beneficial sustained 4-year effect on their CAD risk factors. Secondarily, we assessed the impact of CAC scanning on downstream medical resource utilization and healthcare costs.
Methods
The trial participants consisted of 2,137 subjects who were recruited between May 2001 and May 2005 at Cedars-Sinai Medical Center (CSMC) (Fig. 1) . We preferentially selected middle-aged individuals with CAD risk factors and excluded subjects with a history of cardiac or cerebrovascular disease or chest pain, age Ն80 years, pregnancy, significant medical comorbidity, and prior coronary catheterization or prior CAC scanning. After recruitment, subjects were randomized into a group that was either scheduled for CAC scanning (scan group) or not scheduled for calcium scanning (no-scan group). To encourage subjects' enrollment into our study, the ratio of randomization was 2:1 for receiving a CAC scan. This research was approved by the CSMC institutional review board, and all subjects signed informed consent. Baseline clinical assessment. Baseline measurements were obtained for the following: fasting total cholesterol, highdensity lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting serum glucose; systolic and diastolic blood pressure measurements; height; weight; and waist circumference. Physical activity was assessed dichotomously (yes/no) according to subjects' response to the following question: "Do you exercise regularly (3 to 4 times a week) for at least 30 minutes each time?" Ten-year risk of CAD was calculated by the Framingham Risk Score (FRS) in accordance with published guidelines (5, 6) . Subjects with diabetes mellitus were automatically assigned a high risk FRS of 20%, or higher if so calculated (6) . Risk factor counseling. At the baseline examination, one of our nurse practitioners, each having been trained regarding the need for impartiality and consistency in counseling, conducted a private risk factor counseling session. To further standardize counseling, the nurse practitioner printed a customized risk factor management packet for each subject containing the American Heart Association guidelines on cardiac risk factors (7), subjects' results for each risk factor, and information on how to improve their risk profiles. The nurse practitioner reviewed the packet with each subject first, and then additionally also reviewed the CAC images, and CAC score and percentile score with subjects in the scan group. Subjects were instructed that the presence of any calcium constituted evidence of atherosclerosis. To preserve subject anonymity as required by our institutional review board, test results were not sent directly to subjects' physicians, but subjects were given 2 copies of their anonymized CAC scan report and were encouraged to share their results with their physician. Coronary calcium scanning. Scanning was performed using electron beam (GE-Imatron Inc., San Francisco, California) or multislice computed tomography (Siemens Medical Systems, Forchheim, Germany). The imaging protocol involved acquiring a single scan of ϳ30 to 40 slices of 3 or 2.5 mm thickness (8) . Foci of CAC were identified by an experienced radiographic technologist and scored using semiautomatic commercial software on a NetraMD workstation. Total calcium score was determined by summing lesionspecific scores, calculated as the product of the area of each calcified focus and peak CT number derived according to the Agatston method (9) . Estimated radiation dose ranged from 1 to 2 mSv. 4-year clinic visit. Trial participants were asked to return for a follow-up clinic visit at 4 years, during which all assessments obtained at baseline were repeated and CAC scanning was performed in all subjects. Of the 2,137 enrolled subjects, 713 (33.4%) were randomized to the no-scan group and 1,424 (66.6%) to the scan group (Fig. 1 ). Of these, 584 (81.9%) no-scan and 1,256 (88.2%) scan subjects completed the follow-up clinic evaluation and questionnaire (p Ͻ 0.001). There were 35 (4.9%) no-scan subjects and 38 (2.7%) scan subjects who could not return for the follow-up clinic evaluation and completed the questionnaire only; these subjects were not assessed for clinic-determined risk factors at 4 years. Within the no-scan group, 52 (7.3%) were lost to follow-up, 17 (2.4%) withdrew from the trial, and 4 (0.6%) died before 4-year follow-up. Within the scan group, 61 (4.3%) were lost to follow-up, 13 (0.9%) withdrew, and 17 (1.2%) died before follow-up. There were 21 (2.9%) no-scan subjects and 39 (2.7%) scan subjects who indicated they met eligibility criteria at enrollment but later disclosed an exclusion criterion that resulted in their subsequent exclusion. Three no-scan subjects and 8 scan subjects did not undergo repeat CAC scanning at the time of their 4-year clinic visit. Primary outcomes. The primary outcome of our trial was change in CAD risk profiles at 4 years among the scan subjects versus no-scan subjects, including change in global risk as assessed by the FRS. Secondary outcomes. Secondary outcomes included comparison of the randomized groups relative to rates of downstream tests and procedures, health care costs, and occurrence of adverse clinical events. To assess costs, we applied nationwide, average Medicare diagnosis-related group reimbursement rates using the PC Pricer prospective payment system estimator. Outpatient service costs were derived by use of the outpatient prospective payment amounts (nationwide and specific locality) based on healthcare common procedure codes. The Medicare planner for retail and mailorder pharmacy charges were used to derive drug costs in our Annual event rates were calculated as the % number of events divided by person-years. Progression of CAC scores in the scan group were assessed by comparing the CAC score at 4 years to that at baseline. Relative change in CAC scores were assessed according to the formula developed by the MESA (MultiEthnic Study of Atherosclerosis) study: ln(CACy4ϩ25) Ϫ ln(CACblϩ25). We identified progression of CAC to have occurred if subjects converted from a negative to a positive scan or if subjects were Ն75th percentile for progression by the MESA formula. All clinically relevant predictors were tested using logistic regression with progression as the outcome both Table 2 shows the change in CAD risk factor status in the randomized groups at 4-year follow-up. Compared with the no-scan group, the scan group had significantly greater reduction in systolic blood pressure and serum LDL cholesterol levels, reduction in waist circumference for those with increased abdominal girth at baseline, and modest tendency towards less weight gain among subjects who were overweight (body mass index Ն25 kg/m 2 ). There was no significant difference between the 2 groups with respect to HDL cholesterol, triglyceride, and glucose levels; smoking cessation; and new exercise activity. Notably, the 4-year mean FRS score increased in the no-scan group compared with baseline FRS (0.7 Ϯ 5.1), but remained essentially unchanged in the scan group (0.002 Ϯ 4.9, p ϭ 0.003) even though they were 4 years older.
Comparison of medical resource utilization in the randomized groups. More scan than no-scan subjects had initiation of new antihypertensive medication use, and there was a modest tendency toward greater use of lipid-lowering medications. Within both groups, continuation of lipid lowering and antihypertensive medication remained high at 4 years for those on these medications at baseline. As shown in Table 2 , the 2 randomized groups did not differ in 4-year utilization of stress tests, carotid ultrasound studies, noninvasive and invasive coronary angiogram studies, and revascularization procedures. The overall medical procedure costs were comparable in both randomized groups, although medication costs tended to be higher in the scan group.
Comparison of clinical events in the randomized groups.
Within our study population, there were 3 cardiac deaths (annualized cardiac mortality rate of 0.04%) and 21 all-cause deaths (annualized all-cause mortality rate of 0.3%). One cardiac death (0.2%) and 4 all-cause deaths (0.6%) occurred in the no-scan group, and 2 cardiac deaths (0.2%) and 17 all-cause deaths (1.3%) occurred in the scan group (p ϭ 1.00 for cardiac and p ϭ 0.24 for all-cause mortality). Myocardial infarction occurred in 2 (0.3%) no-scan subjects and 10 (0.8%) scan subjects (p ϭ 0.36). The combined number of deaths and/or myocardial infarction were 6 (1.0%) in the no-scan group and 27 (2.1%) in the scan group (p ϭ 0.08). Impact of baseline CAC score on 4-year CAD risk profiles. Within the scan group, increasing baseline CAC score was associated with a proportionally greater improvement in most CAD risk factors at follow-up (Table 3 ). An inverse dose-response relationship was observed between increasing baseline CAC scores and systolic and diastolic blood pressure, serum cholesterol, LDL cholesterol, and triglycerides. In addition, greater weight loss was noted among overweight subjects with CAC scores Ն100 at baseline, and for subjects with increased abdominal girth, the greater decline occurred among those with CAC scores Ն400 at baseline. There was also a trend toward more exercise with increasing CAC scores. The FRS rose in subjects with a zero CAC score, but decreased in subjects with evidence of CAC at baseline. Impact of baseline CAC score on medical resource utilization. A progressive increase in new cardiac medications occurred with increasing baseline CAC scores, particularly for lipid-lowering medications. Among subjects on medications at baseline, adherence rates at 4 years were high for use of lipid-lowering and antihypertensive medications. The frequency of both noninvasive and invasive procedures as well as procedural costs also increased with increasing baseline CAC scores, but the rate of catheterization and revascularization was low in all groups. Procedural costs were low for subjects with no CAC and much higher for subjects with CAC scores Ն400.
Comparison of the no-scan group to subjects with a normal baseline CAC scan. Comparison of the no-scan randomized group to the scan subgroup with normal CAC scans (CAC score ϭ 0) is shown in Table 4 . There was no difference between these groups in 4-year CAD risk profiles, although the normal scan subjects had lower rates of initiation of new lipid medication. Similarly, adherence to baseline medications did not differ between these groups. Lower downstream rates of noninvasive tests and invasive procedure utilization were noted for subjects with normal CAC scans. Overall, incurred costs were lower in the normal scan subjects compared with the no-scan subjects, including 37% lower procedures costs (p ϭ 0.001) and 26% lower medication costs (p ϭ 0.005). Assessment of CAC scores at 4 years. The CAC score at 4 years was mean 147 Ϯ 335, or median 11 (0, 124) in the no-scan group and mean 163 Ϯ 431 or median 12 (0, 124) in the scan group (p ϭ 0.89). The distribution of CAC scores was similar between the no-scan and scan groups at 4 years: 43% and 42% had a zero CAC score, 29% and 31% had a CAC score of 1 to 99, 18% and 17% had CAC scores of 100 to 399, and 11% in both groups had CAC scores Ն400 (p ϭ 0.75 for all subgroups). Overall, 385 (31%) of the 1,248 scan subjects showed conversion from a normal to abnormal CAC scan (n ϭ 73) or change in CAC score that was Ͼ75th percentile for progression by the MESA formula (n ϭ 273) or both (n ϭ 39). In the baseline predictors model Values are mean Ϯ SD, n (%), or median (25th, 75th percentile). *Test for trend. ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin-receptor blockers; BP ϭ blood pressure; CAD ϭ coronary artery disease; HDL ϭ high-density lipoprotein; LDL ϭ low-density lipoprotein.
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Discussion
To assess the impact of CAC scanning on CAD risk, we randomly assigned asymptomatic subjects to groups undergoing CAC scan versus no CAC scan and compared the groups for 4-year changes in CAD risk. In total, 7 modifiable CAD risk factors were assessed: blood pressure, lipid profiles, serum glucose, weight, waist circumference, exercise, and smoking. Subjects who underwent CAC scanning experienced a favorable improvement in risk, including greater reduction in mean systolic blood pressure and serum LDL cholesterol level, and reduced waist circumference for those with increased abdominal girth at baseline. The overweight subjects within the scan group also showed a tendency toward more weight loss compared with their no-scan counterparts. The 2 groups did not differ in exercise activity, smoking behavior, or glucose measurements at 4 years, but the frequencies of smokers and diabetic patients in our study were both low. Four-year progression of CAD risk, as summarized by FRS, rose in the no-scan group but was static in the scan group, due to the favorable improvements in systolic blood pressure and lipid status. Importantly, risk factor profiles improved in both the scan and no-scan groups after recruitment into our trial, but the magnitude of improvement was greater in the scan group. Overall rates of downstream medical testing and procedures did not differ among the scan and no-scan groups, resulting in comparable medical procedure costs during follow-up. Estimated medication costs were mildly higher in the scan group.
There was no substantive difference in the rates of myocardial infarction or fatal events between the 2 randomized groups; however, the rates of events were low and statistical power was insufficient to adequately assess this issue. Practical study of how CAC scanning might affect clinical events may require studying patients, rather than healthy volunteers, who may be pre-selected to be at higher risk of clinical events compared with our subjects (11) . Change in CAD risk factors, downstream tests, and incurred costs according to baseline CAC score. Within the scan group, there was a direct proportional relationship between the magnitude of baseline CAC and the degree of reduction of systolic and diastolic blood pressure, serum cholesterol, LDL, and triglyceride levels. In addition, a reduction in waist size occurred among subjects with increased abdominal girth and high CAC scores, and modest weight loss occurred among overweight subjects with CAC score elevation. Factors not varying according to CAC score included HDL cholesterol, glucose measurements, and smoking cessation. The composite FRS at 4 years increased compared with the baseline FRS among the scan subjects with a zero CAC score and decreased among subjects with elevated CAC scores.
There was a strong proportional relationship between baseline CAC score and the frequency of initiating cardiac medications. Downstream medical testing also increased in proportion to baseline CAC score. Both procedural and medical costs were substantially higher in the subjects with a CAC score Ն400 compared with subjects having a CAC score of 100 to 399. Noninvasive stress testing predominated among downstream tests. Overall, approximately two-thirds of subjects with CAC scores Ն400 underwent some form of cardiac stress testing, but the frequency of 4-year rates of cardiac catheterization and coronary revascularization were substantially lower. Because of the design of our trial, we were uniquely able to assess how knowledge of a normal CAC scan influenced the forward trajectory of medical treatment and costs compared with usual medical care. Overall, there was a 25% greater reduction in medication costs in the normal CAC scan subjects compared with the no-scan group, and a 37% reduction in procedure costs. Since the normal scan subjects constituted ϳ50% of our scan subjects, whereas the subjects with CAC scores Ն400 constituted only ϳ8% of our scan subjects, these directionally opposite effects were sufficient to result in the comparable incurred costs within our scan and no-scan groups. Assessment of CAC scores at 4 years. There was no difference in mean CAC scores or the distribution of CAC scores in the no-scan versus scan group at 4 years. Within the scan group, we found that both baseline CAD risk factors and the use of lipid-lowering medication were predictors of CAC score progression. These findings parallel that of the MESA study (12) . While some early studies reported that the use of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors (statins) was associated with a reduced rate of CAC progression during serial scanning (13, 14) , subsequent studies have reported either no difference in CAC progression (15) (16) (17) or even increased rate of CAC progression among subjects using such medication (12, 18) . Of note in this regard is experimental work suggesting that statins may have the ability to promote calcification of coronary plaques (19) . While further study is indicated, the apparent multifactorial causation for plaque progression limits the use of CAC score progression as a therapeutic index.
Comparison to prior studies. Only 1 prior randomized trial, conducted by O'Malley et al. (20) , has assessed the impact of CAC scanning on subjects' risk profiles and health behavior, and there are no prior trials concerning the impact of CAC scanning on downstream tests and costs. In the trial conducted by O'Malley et al. (20) , subjects underwent CAC scanning, but the results were then withheld in one-half of subjects. In contrast to our study, these investigators found no impact of CAC scanning on subjects' clinical profile. However, their study was primarily limited to young military personnel with a mean age of only 42 years, and 85% had normal CAC scans, thus limiting the comparability of their findings to our own. Study limitations. Our subjects were highly educated, fairly affluent, and sufficiently motivated to volunteer for our research study, and were thus more likely than a general population to adhere to risk factor modification therapies. Indeed, the ϳ90% 4-year continuation rate for using lipidlowering and antihypertensive medication in our study is atypically high compared with studies involving patient populations (21) . In addition, our study and the prior study by O'Malley et al. (20) are similarly limited in that they involved the offering of free CAC scans to volunteer subjects. This incentive offering may not be reflective of the care path that patients may encounter when confronted with out-of-pocket CAC scan costs from the onset or when the scan is ordered by a physician. For these reasons, caution should be applied in generalizing our findings to populations at large.
Because of the limited assessment of health behaviors in our study, we could not determine the extent to which CAC scanning drove reduced CAD risk profiles due to improvement in subjects' health behaviors as opposed to more intensive use and adherence to medications. An objective measure of dietary habits was lacking in our study, and our assessment of exercise activity relied on a crude self-report measurement rather than on objective measurements, such as can be garnered by pedometer use. Further, the nature of our study design, involving only a 1-time counseling session, might not be ideal for inducing behavioral lifestyle changes that are more difficult to accomplish compared with taking medications. Thus, future study might compare if and what intensity of behavioral interventions improves the ability of CAC scanning to improve patients' lifestyle health behaviors.
The impact of CAC scanning on diabetes and smoking could not be adequately assessed in our trial, owing to our small number of subjects with these risk factors. In addition, we cannot exclude that the nature of our study design led to psychological effects whereby subjects who were randomized to the scan group-and thus received a free CAC scan at both onset and at 4 years-felt more motivated to participate in our trial, and those who were randomized to the no-scan group felt discouraged that CAC scanning would be deferred for 4 years. Potentially, this dynamic might explain the greater loss to follow-up that was noted among the no-scan subjects.
Another important methodological limitation was that due to anonymity restrictions imposed by our institutional review board, we could not provide CAC scan results directly to our subjects' physicians. As a result, their involvement only occurred indirectly. However, this limitation may have served to actually minimize the potential impact of CAC scanning upon risk factor management in our study. Conversely, our study design may have limited our ability to assess the financial impact of CAC scanning in clinical practice, as the actual course of action following calcium scanning may be potentially different when testing is ordered by a physician rather than being initiated by subjects seeking to assess their cardiovascular risk. For example, after their ordering of a CAC scan, physicians may feel more compelled than volunteer subjects to do follow-up stress testing in patients with intermediate to high CAC scores for fear of medicolegal consequences for a missed work-up for myocardial ischemia. Accordingly, more prospective study is required to assess the financial impact of CAC scanning upon downstream testing and medical costs in actual clinical practice. Clinical implications. The results of our trial are consistent with the hypothesis that CAC scanning can improve cardiac management without incurring significant increase in downstream medical costs. Further work should similarly assess patients who are suitable candidates for CAC scanning based on clinical consensus and current guidelines (22) (23) (24) . Notably, the finding that our study did not lead to increased downstream testing is potentially clinically significant, revealing that physicians may be applying a "gatekeeper" function to CAC scanning with respect to ascertaining the need for subsequent more expensive noninvasive testing. This potential use may be based on the repeated observation of a threshold relationship between the magnitude of CAC abnormality and the likelihood of observing inducible myocardial ischemia (8, (25) (26) (27) (28) . The results of our study indicate a need for future large-scale clinical trials to determine whether our findings are applicable to different patient populations and to determine whether the salutatory effect of CAC scanning on CAD risk profiles translates to reductions in adverse clinical events. Such trials should evaluate outcomes following CAC scanning not only according to the efficacy and intensity of medications used to control CAD risk factors, but also according to the quality and intensity of behavioral interventions instituted after CAC scanning.
